The emergence of novel agents including luspatercept and imetelstat have redefined care in lower-risk MDS, while promising novel strategies—including p53 reactivators, CD47 inhibitors, T-cell TIM-3 blockers, and immune checkpoint inhibitors—are reshaping the treatment paradigm in higher-risk disease. Here, CD47 is linked to myelodysplastic syndrome.